- Home
- CXAI vs CRIS Comparison
CXAI vs CRIS Comparison
Compare CXAI & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXAI
- CRIS
- Stock Information
- Founded
- CXAI N/A
- CRIS 2000
- Country
- CXAI United States
- CRIS United States
- Employees
- CXAI N/A
- CRIS N/A
- Industry
- CXAI EDP Services
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CXAI Technology
- CRIS Health Care
- Exchange
- CXAI Nasdaq
- CRIS Nasdaq
- Market Cap
- CXAI 16.0M
- CRIS 22.9M
- IPO Year
- CXAI N/A
- CRIS 2000
- Fundamental
- Price
- CXAI $0.72
- CRIS $1.71
- Analyst Decision
- CXAI
- CRIS Strong Buy
- Analyst Count
- CXAI 0
- CRIS 2
- Target Price
- CXAI N/A
- CRIS $16.50
- AVG Volume (30 Days)
- CXAI 654.3K
- CRIS 74.8K
- Earning Date
- CXAI 11-11-2025
- CRIS 11-13-2025
- Dividend Yield
- CXAI N/A
- CRIS N/A
- EPS Growth
- CXAI N/A
- CRIS N/A
- EPS
- CXAI N/A
- CRIS N/A
- Revenue
- CXAI $6,005,000.00
- CRIS $11,405,000.00
- Revenue This Year
- CXAI N/A
- CRIS $1.41
- Revenue Next Year
- CXAI $60.00
- CRIS $7.46
- P/E Ratio
- CXAI N/A
- CRIS N/A
- Revenue Growth
- CXAI N/A
- CRIS 12.24
- 52 Week Low
- CXAI $0.61
- CRIS $1.02
- 52 Week High
- CXAI $2.54
- CRIS $6.44
- Technical
- Relative Strength Index (RSI)
- CXAI 42.22
- CRIS 48.53
- Support Level
- CXAI $0.70
- CRIS $1.63
- Resistance Level
- CXAI $0.79
- CRIS $1.95
- Average True Range (ATR)
- CXAI 0.05
- CRIS 0.15
- MACD
- CXAI 0.01
- CRIS 0.01
- Stochastic Oscillator
- CXAI 54.37
- CRIS 29.41
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.